Literature DB >> 25613699

PTEN and hTERT gene expression and the correlation with human hepatocellular carcinoma.

Xu Zhou1, Huaqiang Zhu1, Jun Lu2.   

Abstract

The aim of this study was to investigate the correlation between tumor suppressor gene phosphatase and tensin homolog (PTEN) expression levels and telomerase activity that mainly depends on telomerase reverse transcriptase (hTERT) in hepatocellular carcinoma (HCC) and paracancerous tissues. Immunohistochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR) were used to detect the expression of PTEN and hTERT in 58 cases with HCC and the corresponding paracancerous tissues. The correlation between PTEN and hTERT was analyzed. The PTEN mRNA and protein expression was significantly lower in HCC, as compared with the paracancerous tissues (P<0.01), while those of hTERT demonstrated the opposite expression pattern (P<0.01). Additionally, both the PTEN and hTERT protein and mRNA levels demonstrated a significantly negative correlation with one another (P<0.05). In conclusion, PTEN and hTERT have different roles in the development of HCC. A significantly negative correlation between PTEN and hTERT gene expression indicates that hTERT activation and upregulation may be conferred by the loss of PTEN gene expression in HCC. The combined detection of PTEN and hTERT may provide critical clinical evidence for the diagnosis and biological behavior of HCC.
Copyright © 2015. Published by Elsevier GmbH.

Entities:  

Keywords:  Hepatocellular carcinoma; PTEN; hTERT

Mesh:

Substances:

Year:  2014        PMID: 25613699     DOI: 10.1016/j.prp.2014.11.016

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

1.  A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.

Authors:  Katherine K Slemmons; Lisa E S Crose; Stefan Riedel; Manuela Sushnitha; Brian Belyea; Corinne M Linardic
Journal:  Mol Cancer Res       Date:  2017-09-18       Impact factor: 5.852

2.  Heterogeneity of antigenic constellation in human hepatocellular carcinoma.

Authors:  Mihai Ceausu; Bogdan Socea; Dragos Serban; Cătălin Gabriel Smarandache; Dragoş Predescu; Nicolae Bacalbaşa; Iulian Slavu; Adrian Tulin; Lucian Alecu; Zenaida Ceauşu
Journal:  Exp Ther Med       Date:  2021-01-25       Impact factor: 2.447

3.  Targeting NF-κB/AP-2β signaling to enhance antitumor activity of cisplatin by melatonin in hepatocellular carcinoma cells.

Authors:  Jiaojiao Hao; Zhenglin Li; Changlin Zhang; Wendan Yu; Zhipeng Tang; Yixin Li; Xu Feng; Yue Gao; Quentin Liu; Wenlin Huang; Wei Guo; Wuguo Deng
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

Review 4.  Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.

Authors:  Leidy D Caraballo Galva; Lun Cai; Yanxia Shao; Yukai He
Journal:  J Genet Genomics       Date:  2020-01-28       Impact factor: 4.275

5.  PTEN Inhibits Cell Proliferation, Promotes Cell Apoptosis, and Induces Cell Cycle Arrest via Downregulating the PI3K/AKT/hTERT Pathway in Lung Adenocarcinoma A549 Cells.

Authors:  Xiao-Xiao Lu; Lan-Yu Cao; Xi Chen; Jian Xiao; Yong Zou; Qiong Chen
Journal:  Biomed Res Int       Date:  2016-10-16       Impact factor: 3.411

6.  A method to culture human alveolar rhabdomyosarcoma cell lines as rhabdospheres demonstrates an enrichment in stemness and Notch signaling.

Authors:  Katherine K Slemmons; Michael D Deel; Yi-Tzu Lin; Kristianne M Oristian; Nina Kuprasertkul; Katia C Genadry; Po-Han Chen; Jen-Tsan Ashley Chi; Corinne M Linardic
Journal:  Biol Open       Date:  2021-02-09       Impact factor: 2.643

7.  Stanozolol administration combined with exercise leads to decreased telomerase activity possibly associated with liver aging.

Authors:  Eren Ozcagli; Mehtap Kara; Tugba Kotil; Persefoni Fragkiadaki; Manolis N Tzatzarakis; Christina Tsitsimpikou; Polychronis D Stivaktakis; Dimitrios Tsoukalas; Demetrios A Spandidos; Aristides M Tsatsakis; Buket Alpertunga
Journal:  Int J Mol Med       Date:  2018-04-26       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.